Ends: 75d 1h 23min

Innovative therapies for skin diseases

Maximising the value of your assets for patients suffering from a dermatological condition

Our Aim

We are looking for partnering opportunities on new assets (small molecules, biologics, or advanced therapies) in clinical or preclinical development stages that could be used for the treatment of dermatological conditions.

Preferably, the assets should target immuno-inflammatory pathways with rationale for dermatological indications, such as atopic dermatitis, hidradenitis suppurativa, alopecia areata, and vitiligo, or be suitable for non-melanoma skin cancer, or rare dermatological indications.

Our interest

New assets in clinical or preclinical development stages

What we offer

Access to our expertise in dermatological R&D

Your benefit

A partnership opportunity

Shared goal

Finding innovative therapies for patients

Who is this for?

Universities

Biotechs

Public and private research institutions

Start-ups

Pharmaceutical companies

Collaborative framework

Submitted proposals may be eligible for a clinical or preclinical development partnership

You will retain ownership of any intellectual property you may bring or develop

Assets might be characterised on key dermatological in vitro and in vivo assays

A designated contact person will help answer your questions

Submitted proposals may be eligible for a clinical or preclinical development partnership

You will retain ownership of any intellectual property you may bring or develop

Assets might be characterised on key dermatological in vitro and in vivo assays

A designated contact person will help answer your questions

Collaboration process

1 2 3 Proposal submission From July 20th, 2022 to October 31st, 2022 Submissions will be handled following all applicable local compliance requirements Proposal evaluation and selection Within 4-8 weeks after submission

Collaboration process

1

Proposal submission

From July 20th, 2022 to October 31st, 2022

2

Submissions will be handled following all applicable local compliance requirements

3

Proposal evaluation and selection

Within 4-8 weeks after submission

Innovative therapies for skin diseases